191 related articles for article (PubMed ID: 1846551)
1. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
Nicholson S; Richard J; Sainsbury C; Halcrow P; Kelly P; Angus B; Wright C; Henry J; Farndon JR; Harris AL
Br J Cancer; 1991 Jan; 63(1):146-50. PubMed ID: 1846551
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and other oncogenes as prognostic markers.
Harris AL; Nicholson S; Sainsbury R; Wright C; Farndon J
J Natl Cancer Inst Monogr; 1992; (11):181-7. PubMed ID: 1627426
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure.
Nicholson S; Wright C; Sainsbury JR; Halcrow P; Kelly P; Angus B; Farndon JR; Harris AL
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):811-4. PubMed ID: 2285594
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
[TBL] [Abstract][Full Text] [Related]
5. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.
Fox SB; Smith K; Hollyer J; Greenall M; Hastrich D; Harris AL
Breast Cancer Res Treat; 1994 Jan; 29(1):41-9. PubMed ID: 8018963
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
[TBL] [Abstract][Full Text] [Related]
7. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
Sainsbury JR; Farndon JR; Needham GK; Malcolm AJ; Harris AL
Lancet; 1987 Jun; 1(8547):1398-402. PubMed ID: 2884496
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.
Toi M; Osaki A; Yamada H; Toge T
Eur J Cancer; 1991; 27(8):977-80. PubMed ID: 1832907
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up.
Ferrero JM; Ramaioli A; Largillier R; Formento JL; Francoual M; Ettore F; Namer M; Milano G
Ann Oncol; 2001 Jun; 12(6):841-6. PubMed ID: 11484962
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
Nicholson S; Halcrow P; Sainsbury JR; Angus B; Chambers P; Farndon JR; Harris AL
Br J Cancer; 1988 Dec; 58(6):810-4. PubMed ID: 3224082
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of prognostic factors in operable breast cancer.
Hawkins RA; Tesdale AL; Killen ME; Jack WJ; Chetty U; Dixon JM; Hulme MJ; Prescott RJ; McIntyre MA; Miller WR
Br J Cancer; 1996 Nov; 74(9):1469-78. PubMed ID: 8912547
[TBL] [Abstract][Full Text] [Related]
12. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.
Gasparini G; Bevilacqua P; Pozza F; Meli S; Boracchi P; Marubini E; Sainsbury JR
Br J Cancer; 1992 Nov; 66(5):970-6. PubMed ID: 1419645
[TBL] [Abstract][Full Text] [Related]
13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
14. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of transforming growth factors in human breast cancer.
Murray PA; Barrett-Lee P; Travers M; Luqmani Y; Powles T; Coombes RC
Br J Cancer; 1993 Jun; 67(6):1408-12. PubMed ID: 8390290
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
Breast Cancer Res Treat; 2002 Jan; 71(1):67-75. PubMed ID: 11859875
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of epidermal growth factor receptor in node-positive breast cancer.
Grimaux M; Romain S; Remvikos Y; Martin PM; Magdelénat H
Breast Cancer Res Treat; 1989 Oct; 14(1):77-90. PubMed ID: 2690971
[TBL] [Abstract][Full Text] [Related]
18. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic value of EGFR in invasive breast cancer.
Quintela I; Corte MD; Allende MT; Vazquez J; Rodríguez JC; Bongera M; Lamelas M; Gonzalez LO; Vega A; García-Muñiz JL; Astudillo A; Vizoso F
Oncol Rep; 2005 Dec; 14(6):1655-63. PubMed ID: 16273272
[TBL] [Abstract][Full Text] [Related]
20. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
Nicholson S; Sainsbury JR; Halcrow P; Chambers P; Farndon JR; Harris AL
Lancet; 1989 Jan; 1(8631):182-5. PubMed ID: 2463445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
